petosemtamab (MCLA-158) / Merus  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
petosemtamab (MCLA-158) / Merus
2017-004745-24: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors

Not yet recruiting
1/2
567
Europe
MCLA-158, Solution for infusion
Merus N.V., Merus N.V.
Metastatic colorectal cancerAdvanced solid tumors, Colon cancerOther solid tumors, Diseases [C] - Cancer [C04]
 
 
MCLA-158-CL01, NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
360
Europe, US
MCLA-158, petosemtamab, MCLA-158 +Pembrolizumab
Merus N.V., Chiltern International Inc., Q2 Solutions, Oncology Therapeutic Development (OTD), 4Clinics
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma
06/24
06/25

Download Options